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Introduction: To determine the time to progression (TTP), response 
rate (RR), and toxicity for North American patients with relapsed 
small-cell lung cancer (SCLC) treated with bendamustine in the sec-
ond- or third-line setting.
Methods: Patients with relapsed, histologically confirmed SCLC 
were eligible for enrollment on study. The study population included 
patients with both chemotherapy-sensitive and chemotherapy-
resistant disease treated with up to two prior lines of chemotherapy. 
Patients were treated with 120 mg/m2 of bendamustine on days 1 and 
2 of a 21-day cycle for up to six cycles. Primary end point was TTP; 
secondary end points included toxicity, RR, and overall survival.
Results: Fifty-nine patients were accrued, 50 patients met eligibility 
for enrollment. The median age of patients was 62, and 56% were 
men. Twenty-nine patients (58%) had chemotherapy-sensitive dis-
ease. Median TTP was 4.0 months (95% confidence interval [CI], 
3.3–5.4), median overall survival was 4.8 months (95% CI, 3.8–6.3), 
and the RR was 26% (95% CI, 13.3%–39.5%). Patients with chemo-
sensitive disease had a median TTP of 4.2 months (95% CI, 3.3–6.0) 
compared with 3.4 months (95% CI, 2.7–∞) for chemotherapy-resis-
tant disease. The RR was 33% (95% CI, 14.2%–51.8%) in patients 
with chemosensitive disease and 17% (95% CI, 0%–34.4%) in those 
with chemoresistant disease. The most common grade 3/4 adverse 
events were fatigue (20%), dyspnea (12%), and anemia (12%).
Conclusion: Bendamustine has modest activity in relapsed SCLC 
similar to other agents evaluated in this patient population.
Key Words: Bendamustine, Small-cell lung cancer, Relapsed, 
Refractory, Phase II.
(J Thorac Oncol. 2014;9: 559–562)
An estimated 246,210 new cases of lung cancer were diagnosed in the United States in 2013.1 Small-cell lung 
cancer (SCLC) will account for 12% to 15% of these cases. 
Approximately 60% to 70% of patients are diagnosed with 
extensive-stage disease at presentation. Despite response rates 
(RRs) of up to 80% to first-line therapy, the majority of patients 
eventually relapse with a median survival of 18 to 24 months for 
patients with limited-stage disease and 6 to 12 months for patients 
with extensive-stage disease.2 The prognosis is especially poor 
for patients who relapse or progress after first-line therapy within 
the first 3 months. Currently, topotecan is the only U.S. Food and 
Drug Administration–approved agent for use in patients with 
relapsed SCLC.3,4 A multitude of trials have investigated other 
chemotherapy agents in patients with relapsed SCLC, but none 
have proven efficacy over topotecan’s limited benefit.
It is readily understood that there is a considerable need 
for improved therapies for patients with SCLC. Bendamustine is 
a bifunctional alkylating agent which is approved by Food and 
Drug Administration for use as first-line therapy for chronic 
lymphocytic lymphoma5 and for rituximab-refractory indolent 
non-Hodgkin’s lymphoma.6,7 A European phase II study of single-
agent bendamustine in patients with relapsed chemosensitive 
SCLC reported an RR of 29%, a median overall survival (OS) 
of 7 months, and the toxicity profile seemed to be superior when 
compared with toxicities compiled from studies of topotecan.8
Bendamustine has not been evaluated in a North 
American patient population with relapsed SCLC. To further 
evaluate the efficacy and toxicity of this promising agent, 
we conducted a single-arm, phase II study of bendamustine 
as a single-agent in relapsed SCLC, in patients with both 
chemosensitive and chemoresistant disease. The primary end 
point was time to progression (TTP). Secondary end points 
included RR, OS, and toxicity.
PATIENTS AND METHODS
Patient Population
Eligible patients were recruited from Vanderbilt-Ingram 
Cancer Center Affiliated Network sites. Patients were aged 
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18 years or older, had Eastern Cooperative Oncology Group 
performance status (ECOG PS) of 0 to 2, and had received 
up to two prior lines of chemotherapy, one of which must 
have been a platinum-containing regimen. Patients with 
symptomatic or untreated brain metastases were excluded. All 
patients signed informed consent. Chemoresistant disease was 
defined as no response to platinum-containing regimen and/or 
progression of disease within 90 days of treatment with a 
platinum-containing chemotherapy regimen; chemosensitive 
disease was defined as stable disease (SD) or response to 
platinum-containing chemotherapy that lasted at least 90 days. 
The Vanderbilt Medical Center Institutional Review Board 
approved this study.
Treatment Strategy
Patients were treated with 120 mg/m2 of bendamustine 
intravenously on days 1 and 2 of a 21-day schedule. 
Erythropoesis-stimulating agents and granulocyte colony–
stimulating factors were allowed at the discretion of the 
investigator, consistent with American Society of Clinical 
Oncology guidelines. Disease assessment with computed 
tomography scans was repeated every two cycles. Toxicities 
were tabulated using National Cancer Institute Common 
Toxicity Criteria version 2.0. Response was evaluated using 
Response Evaluation Criteria in Solid Tumors 1.0. Patients 
with evidence of a response to treatment or SD in the absence 
of unacceptable toxicity were treated up to a maximum of six 
cycles.
Statistical Methods
Sample Size Estimation and Power Calculation
The primary objective of this phase II trial was to 
evaluate the median TTP. Secondary objectives included RR, 
OS, and toxicity. The sample size estimation was completed 
a priori using the one sample test on the basis of exponential 
distribution. A sample size of 42 provided at least 80% power 
to detect a 50% improvement of the median TTP from previous 
studies of topotecan with two-sided type I error of 5%. The 
null hypothesis was that treatment with bendamustine would 
not result in a TTP of 4.5 months. The power analysis was on 
the basis of assumptions of an accrual time of 18 months and 
an additional 12 months of follow-up.
Statistical Analysis Plan
TTP and OS were estimated using the Kaplan–Meier 
method with the 95% confidence interval (CI). Survival for the 
chemosensitive population and the chemoresistant population 
was compared with the log-rank test. Adverse medical events, 
including National Cancer Institute toxicity grade 3 and grade 
4 laboratory abnormalities were tabulated.
RESULTS
From September 2009 to February 2012, a total of 59 
patients were consented and 50 patients underwent treatment 
on study. Of the nine patients who did not begin treatment, 
four were excluded because of laboratory abnormalities, 
three required urgent radiation therapy, and two had a decline 
in PS after signing consent and before starting on therapy. 
Patient characteristics are included in Table 1. The median 
age was 62 years, 56% were men, and 84% of patients had 
ECOG PS 0 to 1. Twenty-one patients (42%) had received 
two prior lines of chemotherapy. The median TTP from first-
line chemotherapy was 6 months. Twenty-nine patients (58%) 
had chemosensitive disease and 21 (42%) had chemoresistant 
disease.
Median TTP was 4.0 months (95% CI, 3.3–5.4 months) 
(Fig. 1A); patients with chemosensitive disease had a median 
TTP of 4.2 months (95% CI, 3.3–6.0 months) and those with 
chemoresistant disease had a median TTP of 3.4 months 
(95% CI, 2.7–∞ months) (Fig. 1B). Median OS was 4.8 
months (95% CI, 3.8–6.3 months) (Fig. 2A). Patients with 
chemosensitive disease had a median OS of 5.7 months (95% 
CI, 4.1–7.4 months) and patients with chemoresistant disease 
had a median OS of 4.1 months (95% CI, 2.5–7.9 months) 
(Fig. 2B). Forty-two patients were evaluable for response, one 
patient had a complete response, 10 had partial response, and 
17 patients had SD as the best response. Therefore, the RR 
was 26% (95% CI, 13.3%–39.5%) and the overall clinical 
benefit (complete response + partial response + SD) was 67%. 
Fourteen patients had progressive disease at the first evaluation. 
Thirty-three percent of patients (95% CI, 14.2%–51.8%) with 
chemosensitive disease had a response to therapy and 17% 
of patients (95% CI, 0%–34.4%) with chemoresistant disease 
had a response to therapy.
Toxicity
The most common adverse events (AEs) from this study 
are listed in Table 2. There were no grade 5 AEs related to 
TABLE 1.  Patient Characteristics
Characteristic No. of Patients (%)
Age (yr)
 Median 62
 Range 44–77
Sex
 Men 28 (56%)
 Women 22 (44%)
Race
 White 48 (96%)
 African-American 2 (4%)
ECOG PS
 0 14 (28%)
 1 28 (56%)
 2 8 (16%)
Previous no. of chemotherapies
 1 29 (58%)
 2 21 (42%)
Previous radiation therapy
 Yes 38 (76%)
 No 12 (24%)
Chemosensitive disease 29 (58%)
Chemoresistant disease 21 (42%)
ECOG PS, Eastern Cooperative Oncology Group performance status.
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bendamustine. The most common grade 3/4 AEs were fatigue, 
dyspnea, and anemia experienced by 20%, 12%, and 12%, 
respectively. Twelve patients experienced a serious AE that 
required 15 separate hospitalizations while on the study. The 
reasons for hospitalization included dyspnea (3 episodes), 
anemia (2), bronchitis (2), diarrhea (2), neutropenic fever (2), 
pneumonia (1), nausea/vomiting (1), pain (1), and hip fracture 
(1). The rate of grade 3/4 febrile neutropenia was 4%, sensory 
neuropathy was 2%, and 4% of patients experienced any grade 
alopecia.
DISCUSSION
In this single-arm, phase II study, bendamustine had 
modest activity and was well tolerated in patients with relapsed 
chemotherapy-sensitive and chemotherapy-resistant SCLC. 
Treatment with bendamustine resulted in a median TTP of 
4.0 months (95% CI, 3.3–5.4 months) and did not meet the 
prespecified primary end point of a median TTP of 4.5 months. 
Although crosscomparison studies are difficult, the RR and 
survival in patients with relapsed chemosensitive disease 
seem similar to results from a previous study of bendamustine 
FIGURE 1. A, TTP; Kaplan–Meier curve showing TTP with 95% CI of 50 patients treated with bendamustine for relapsed SCLC. 
The median TTP in this population was 4.0 months (95% CI, 3.3–5.4 months). B, TTP in chemosensitive and chemoresistant 
disease. Kaplan–Meier curves showing TTP with 95% CI of 29 patients treated with bendamustine for relapsed SCLC with 
chemosensitive disease and TTP with 95% CI of 21 patients treated with bendamustine for relapsed SCLC with chemoresistant 
disease. The median TTP in patients with chemosensitive disease was 4.2 months (95% CI, 3.3–6.0 months) and those with 
chemoresistant disease had a median TTP of 3.4 months (95% CI, 2.7–∞ months). There was no difference in median TTP 
between the two groups (p = 0.41). TTP, time to progression; CI, confidence interval; SCLC, small-cell lung cancer.
FIGURE 2. A, OS; Kaplan–Meier curve showing OS with 95% CI of 50 patients treated with bendamustine for relapsed SCLC. 
The median OS in this population was 4.8 months (95% CI, 3.8–6.3 months). B, OS in chemosensitive and chemoresistant 
disease. Kaplan–Meier curves showing OS with 95% CI of 29 patients treated with bendamustine for relapsed SCLC with 
chemosensitive disease and OS with 95% CI of 21 patients treated with bendamustine for relapsed SCLC with chemoresistant 
disease. Patients with chemosensitive disease had a median OS of 5.7 months (95% CI, 4.1–7.4 months) and patients with 
chemoresistant disease had a median OS of 4.1 months (95% CI, 2.5–7.9 months). There was no difference in median OS 
between the two groups (p = 0.53). OS, overall survival; CI, confidence interval; SCLC, small-cell lung cancer.
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conducted in Europe.8 This study, however, provides the first 
evidence that bendamustine has activity in patients with 
chemotherapy-resistant disease. This study was conducted in 
patients who are likely to be representative of the majority of 
patients with relapsed SCLC as the study included those with 
ECOG PS of 2 and patients with up to two prior lines or therapy.
In the last 20 years, median survival for patients with 
chemotherapy-resistant SCLC has not appreciably changed.9 
Multidrug regimens studied in relapsed SCLC have generally 
shown improved RRs compared with single agents, but 
this has not translated into a survival benefit. In addition, a 
multitude of chemotherapy drugs and targeted agents tested 
as single agents in phase II studies in patients with relapsed 
SCLC have also not shown superiority to topotecan.
In the current study, bendamustine was generally well 
tolerated. Fatigue, anemia, and thrombocytopenia were the 
most common side effects and were found in similar numbers 
of patients compared with previous studies of bendamustine.5–8 
The rate of grade 3/4 drug-related hematological toxicity 
and febrile neutropenia was lower than the rate reported in 
clinical trials of topotecan used for this disease.10 Importantly, 
bendamustine does not commonly cause alopecia which 
can be  a concern for many lung cancer patients receiving 
chemotherapy.11,12 It also does not routinely cause either 
neuropathy or infusion reactions, and as such, does not require 
corticosteroids for premedication.
Bendamustine has shown efficacy in this population 
in two separate studies, and because of attractive side effect 
profile, it may be an option for use in patients with relapsed 
and/or resistant SCLC. A larger phase III study will be required 
to prove improved efficacy and quality of life of bendamustine 
compared with topotecan.
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TABLE 2.  Adverse Events
Toxicity
Grade 1/2 AE
N (%)
Grade 3/4 AE
N (%)
Bone marrow
 Anemia 22 (44%) 6 (12%)
 Neutropenia 4 (8%) 2 (4%)
 Thrombocytopenia 15 (30%) 2 (4%)
Constitutional symptoms
 Fatigue 17 (34%) 10 (20%)
 Weight loss 9 (18%) 1 (2%)
 Alopecia 2 (4%) 0 (0%)
Metabolic/laboratory
 Hyponatremia 5 (10%) 4 (8%)
 Hyperglycemia 7 (14%) 1 (2%)
Pulmonary
 Dyspnea 10 (20%) 6 (12%)
 Cough 7 (14%) 1 (2%)
Gastrointestinal
 Nausea 20 (40%) 3 (6%)
 Vomiting 15 (30%) 0 (0%)
 Diarrhea 7 (14%) 3 (6%)
 Constipation 9 (18%) 0 (0%)
Infection
 Febrile neutropenia 0 (0%) 2 (4%)
Neurologic
 Sensory neuropathy 2 (4%) 1 (2%)
AE, adverse event.
